Mammography Market Size, Share & Trends Analysis Report By Product (Film Screen, Digital), By Technology (Breast Tomosynthesis, CAD, Digital), By End-use (Specialty Clinics, Hospitals), And Segment Forecasts, 2022 - 2030

Report Overview

The global mammography market size was valued at USD 1.95 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.26% from 2022 to 2030. The rising prevalence of breast cancer and increasing demand for early-stage diagnosis among patients are some of the key factors anticipated to drive demand for breast cancer diagnostic devices over the forecast period. Increased access to breast cancer screening systems and growing government initiatives to support clinical interpretation are some of the pivotal factors expected to propel the industry's growth. For instance:

• The Health Resources & Services Administration (HRSA) introduced a healthcare program to increase the screening procedures in medically underserved areas

• Breast Screen Australia is a collaborative initiative of the Australian and state and territory governments that aims at reducing breast cancer illness and death by detecting the disease early. Women over the age of 40 years are eligible for a free mammography every two years, and women aged 50 to 74 years are actively encouraged to screen

• In October 2021, the government in Goa launched an initiative for free breast cancer screening for 1 lakh women. Breast cancer screening will be carried out at 35 Health Centres across Goa as part of this campaign

Thereby, such factors are expected to positively influence the industry in the coming years. The COVID-19 pandemic resulted in significant reductions in cancer screening, cancer management visits, and cancer procedures across the globe. According to a study in the Journal of the American College of Radiology, at the peak of the pandemic in 2020, mammograms dropped to a dramatic low, reducing by up to 92% in some areas in the U.S. According to the FDA, the number of women examined for breast cancer in 2021 was 38.8 million, implying that hundreds of thousands of women in the U.S. may have missed or delayed screenings owing to the pandemic. This decline in screening volume caused by COVID-19 has presented radiologists with additional challenges.

The repercussions of delayed cancer detection owing to COVID-19 were investigated in a study undertaken in the U.K. and published in the Lancet Oncology in March 2021. The study covered data from over 100,000 people with breast, colorectal, esophageal, or lung cancer. The study found that 1 and 5-year cancer survival rates will be severely reduced because of the outbreak of COVID-19, owing to the lack of availability of screening services. As a result of lockdowns, screening services were disrupted to some extent, which lowered the demand for mammography systems. This negatively impacted the industry.

However, numerous physician reports from the U.S. have observed a growing number of screening appointments during the last quarter of 2020, which is expected to continually rise to reach pre-COVID levels by the latter half of 2021. In addition, with the adoption of AI technologies on a larger scale clinicians will be able to manage their workload more effectively and with more precision, potentially reducing inequities in patient care. A number of screening mammograms is expected to witness an increasing trend post-pandemic. This will positively contribute to the industry's growth in the coming years.

Furthermore, as the world’s population is rising, a large proportion of women might reach the age of 60 years or older. Women over the age of 60 years account for about 78% of all breast cancer-related fatalities. Breast cancer has a high incidence and fatality rate in this age range, indicating significant unmet demand for breast cancer diagnostics. The need for mammography is likely to rise as the number of events and fatalities rises. Thus, the increasing geriatric population is expected to propel the market growth in the forecast period. The introduction of new products in the industry is expected to boost the adoption rate among end-users.

An earlier generation of mammography systems provided 2D images of the breast, which limits the interpretation quality. 2D mammography systems provide Craniocaudal (CC) and Mediolateral-Oblique (MLO) images. The flat nature of these images makes it difficult for physicians to interpret images and identify tumors due to overlapping of tissues and calcifications, which masks cancerous lesions. With the introduction of new 3D-based technology called Digital Breast Tomosynthesis (DBT), it is possible to obtain a 3D image of the breast. This allows radiologists to scan the breast slice by slice and identify abnormalities, which would be obscured in 2D images.

Product Insights

The digital systems segment dominated the industry with a revenue share of more than 60.75% in 2021 and is expected to witness considerable growth over the forecast period. Many organizations took decisive measures to manage these diseases because breast cancer patients are at a higher risk of contracting the infection. According to a study published in Medicina Clinica Journal in September 2020 by Dafina Petrova et al., the European Society for Medical Oncology (ESMO), the Spanish Society of Radiation Oncology (SEOR), and the Spanish Society of Medical Oncology (SEOM) have published some guidelines on how to modify treatment protocols to minimize risks in cancer patients.

The enhanced guidelines might allow for more efficient surgical procedures, which would benefit treatments. Such occurrences are expected to contribute to the growth of the digital systems market. A further aspect of the segmental expansion is product introductions. For instance, FUJIFILM Medical Systems U.S.A., Inc. introduced ScreenPoint Medical’s FDA-cleared Transpara powered by Fusion AI for 2D and 3D mammography in the United States in August 2021. The “Harmony” version of Fujifilm Europe GmbH’s Amulet Innovality mammography equipment was also introduced in Germany in April 2021. AMULET Innovality is a Full Field Digital Mammography (FFDM) that uses Fujifilm’s special and cutting-edge technology to produce the best images with the least amount of radiation exposure to the patient.

Therefore, despite the new technology’s cost being greater than that of conventional systems, digital mammography is becoming the screening method of choice. The 3D systems segment is anticipated to register the fastest CAGR over the forecast period. This is owing to several advantages due to which hospitals & diagnostic clinics are switching to 3D systems as 2D systems are often ineffective in detecting every sign of cancer, increasing the need for additional screenings, which, in turn, increases the overall diagnostic cost. Moreover, the widespread adoption of 3D systems is owing to technological benefits, such as increased breast cancer detection rates, the ability to manage bigger procedure volumes, and a more advantageous reimbursement scenario.

Furthermore, the trend of 3D mammography system leasing contract agreements is increasing. Rental contract agreements allow end-users to pay a set fee for each 3D mammogram conducted utilizing 3D mammography technology provided by manufacturers at no cost. This enables low-income hospitals and diagnostic labs to implement this cutting-edge breast imaging technology. In addition, in recent years, some countries implemented public mammography screening. In these programs, 3D mammography devices are employed to achieve the highest level of accuracy in the identification of breast cancer. Thus, the aforementioned factors are anticipated to contribute to the segment’s growth in the coming years.

End-use Insights

The hospitals segment dominated the end-use segment in 2021 with a revenue share of more than 45.00%. The presence of mammography facilities within a hospital can positively affect various factors, such as duration of hospital stay, total healthcare cost, quality of care, and availability of emergency care. For instance, in September 2019, Parkside Hospital in Wimbledon installed a 3Dmammography system from Hologic that enables high-resolution breast tomosynthesis. Large-scale hospitals usually have in-house mammography facilities; however, the requirement of high investments & frequent maintenance, space, and skilled professionals can act as an entry barrier.

This can burden hospitals trying to manage their medical imaging facilities. To reduce this burden and to increase the reach of their facilities and services, hospitals can partner up with diagnostic centers for providing medical imaging facilities. The diagnostic centers segment is expected to witness significant growth during the forecast period, owing to an increase in awareness about breast cancer. This has accelerated the demand for mammography procedures used for diagnosis, treatment planning, and prevention of breast cancer. The availability of advanced mammography services in diagnostic centers of developed & developing economies, such as the U.S., Germany, the U.K., Japan, China, and India, is expected to propel the overall segment growth.

Technology Insights

In 2021, the digital mammography technology segment accounted for the maximum revenue share of more than 66.85% owing to the various advantages of digital mammography technology. Digital mammography is a specialized and sophisticated form of mammography that examines breast tissue for the presence of cancers using digital sensors and computers rather than X-ray films. In most countries, conventional Screen-Film Mammography (SFM) with a high spatial resolution has been the preferred choice for screening programs. However, with the introduction of digital mammography, a growing number of countries are shifting toward these newer systems, owing to their superior depiction of low-contrast objects, wider dynamic change, and enhanced diagnostic quality of images, particularly when evaluating denser breasts.

Moreover, they also have the added benefit of soft-copy visual displays and soft-copy reading, both of which are easily transferable. Mammography screening is now digital in many nations, including the United Kingdom, providing greater precision, higher quality, and greater efficiency. As a result, digital mammography is becoming the standard screening method, despite the fact that the new equipment is six times more expensive than traditional systems. Furthermore, in comparison to analog systems, radiation exposure is reduced significantly. The most prevalent type of digital mammography used is full-field digital mammography. It has the potential to make substantial advancements in breast cancer diagnostics, such as lowering radiation doses, reducing breast compression pressure, and improving detection.

All of these benefits will contribute to the market’s growth over the forecast period. The breast tomosynthesis technology segment is expected to witness the fastest CAGR over the forecast period. Digital breast tomosynthesis is a high-resolution limited-angle tomography technology that uses X-rays to create a 3-dimensional image of the breast. It is a new technique that aids in the identification of breast cancer in its early stages. Digital breast tomosynthesis is very useful in analyzing dense breasts and can enhance the ability to detect breast cancer. It minimizes the number of false-positive readings (readings that identify normal tissue as abnormal) and the necessity for a biopsy.

It is especially good for those with dense breasts. Furthermore, a number of major studies have indicated that combined 2D/3D mammography systems are superior to 2D mammography alone in the diagnosis of breast cancer. A large-scale study performed in the U.S. of 4,54,850 patients observed that combined 2D/3D combination screening detected 5.5 cancers per 1,000 women, compared to 4.3 cancers for 2D screening alone, a 28% higher detection rate with combined 2D/3D mammography systems, according to the American Society of Clinical Oncology (ASCO) clinical trial report. Thus, increasing awareness about the usage of these systems, as well as high detection rates, are the primary factors driving the segment's growth.

Regional Insights

North America dominated the global industry in 2021 with a revenue share of around 36.4% and is expected to exhibit a considerable growth rate over the forecast period. The rising incidence of breast cancer is one of the major factors driving the regional market. According to the American Cancer Society, an approximate 276,480 new cases of invasive breast cancer among women would be detected in 2020. Furthermore, 48,530 cases of in situ breast carcinoma in women have been discovered, and the number of breast cancer cases is predicted to rise in the coming years. Moreover, numerous companies have begun to establish initiatives to assist with breast cancer tests.

For example, Hologic Inc. announced the beginning of the Back to Screening campaign in August 2020, which may motivate women to schedule their postponed mammograms due to the COVID-19 pandemic. The National Breast Cancer Foundation (NBCF) is the organization in the United States that offers breast cancer education and free mammograms to women in need. In addition, the presence of highly developed healthcare infrastructure and increasing healthcare spending are among the key factors anticipated to drive the industry growth over the forecast period. Asia Pacific is anticipated to witness the fastest CAGR over the forecast period.

The increased prevalence of breast cancer, high R&D investments in breast cancer therapies, and developments in breast imaging modalities are the primary drivers responsible for the growth of the Asia-Pacific market. Breast cancer is the most frequent malignancy in most Asian countries regardless of race or ethnicity, according to the Centers for Disease Control and Prevention (CDC). According to GLOBOCAN 2018, the age-standardized incidence rate of breast cancer in Asia is 34.4 per 100,000 people. Thus, the increased prevalence of breast cancer and the region’s expanding healthcare infrastructure are likely to fuel overall growth. The presence of developing countries, such as China, Japan, and India, is anticipated to boost the region’s growth further. In addition, key players are making constant efforts to enter emerging markets in Asia Pacific.

Key Companies & Market Share Insights

The global industry is consolidated due to the presence of a few major players. The key players are focusing on technological advancements and reducing the side effects of the procedures. These companies have a wide product portfolio, which includes breast tomosynthesis, digital mammography, computer-aided detection, and breast biopsy devices. The industry participants are actively involved in multiple strategic initiatives to maintain their position in the market.

For instance, in December 2020, Hologic Inc., a developer, producer, and provider of high-quality diagnostics, and medical imaging devices announced U.S. FDA clearance for its Genius AI Detection technology, a new deep learning-based software designed to aid radiologists to detect subtle potential cancers in breast tomosynthesis images. Thus, with the above-mentioned strategies, the industry is predicted to impel during the forecast period. Some of the key players in the global mammography market include:

• Hologic Inc.

• Analogic Corporation,

• Canon Medical Systems Corporation,

• Fujifilm Corporation

• Siemens Healthcare

• Toshiba Medical Systems

• GE Healthcare

• Metaltronica

• Koninklijke Philips NV

• PLANMED OY

Mammography Market Report Scope

Global Mammography Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global mammography market report on the basis of product, technology, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Film Screen Systems

  • Digital Systems

  • Analog Systems

  • 3D Systems

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Breast Tomosynthesis

  • CAD Mammography

  • Digital Mammography

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Specialty Clinics

  • Diagnosis Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

  • Latin America

    • Mexico

    • Brazil

    • Argentina

    • Colombia

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE